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Abstract Mutations in SCN8A are associated with epilepsy
and intellectual disability. SCN8A encodes for sodium channel
Nav1.6, which is located in the brain. Gain-of-function mis-
sense mutations in SCN8A are thought to lead to increased
firing of excitatory neurons containing Nav1.6, and therefore
to lead to increased seizure susceptibility. We hypothesized
that sodium channel blockers could have a beneficial effect
in patients with SCN8A-related epilepsy by blocking the over-
active Nav1.6 and thereby counteracting the effect of the mu-
tation. Herein, we describe 4 patients with a missense SCN8A
mutation and epilepsy who all show a remarkably good re-
sponse on high doses of phenytoin and loss of seizure control
when phenytoin medication was reduced, while side effects
were relatively mild. In 2 patients, repeated withdrawal of
phenytoin led to the reoccurrence of seizures. Based on the
findings in these patients and the underlying molecular mech-
anism we consider treatment with (high-dose) phenytoin as a
possible treatment option in patients with difficult-to-control
seizures due to an SCN8A mutation.
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Introduction
Mutations in SCN8A have recently been described in patients
with epileptic encephalopathy, intellectual disability, and de-
velopmental delay [1–4]. SCN8A encodes for the sodium
channel Nav1.6, one of the major voltage-gated sodium chan-
nels (VGSC) in the central nervous system, playing an impor-
tant role in action potential propagation and spread.
Other VGSC subtypes expressed in the human brain
are Nav1.1, Nav1.2, and Nav1.3, encoded by SCN1A,
SCN2A, and SCN3A, respectively. Nav1.3 primarily
plays a role in the embryonic and early neonatal brain.
Nav1.1 is located at inhibitory neurons, while Nav1.2
and Nav1.6 are the main channels in excitatory neurons
[5]. Nav1.2 and Nav1.6 are located in the axon initial
segment, which is where action potentials are initiated
depending on the net result of excitatory and inhibitory
signals the neuron receives. Nav1.6 regulates persistent
and resurgent current and is voltage dependent. Persis-
tent current is a steady state after firing of the cell,
which is important for repetitive firing of the neuron,
while resurgent current can occur after initial depolari-
zation and prevents normal inactivation of the channel
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after depolarization, promoting the firing of another ac-
tion potential. This allows neurons to fire quickly and
repetitively [6]. These properties make Nav1.6 an im-
portant channel in neuronal excitability regulation.
In 2012, Veeramah et al. [1] were the first to de-
scribe a de novo SCN8A mutation in a patient with
infantile epileptic encephalopathy. The patient had sei-
zure onset at 6 months of age, developmental delay,
features of autism, ataxia, and intellectual disability.
She died at the age of 15 years from sudden unex-
plained death in epilepsy. Using whole genome se-
quencing, a p.Asn1768Asp mutation was detected in
the patient, which was not found in her healthy parents
nor her unaffected sibling. Functional studies showed
persistent channel activation and incomplete channel
inactivation, hereby contributing to increased firing
[1]. After this publication, various other missense
SCN8A mutations in patients with epileptic encephalop-
athy have been described [2, 4, 7, 8]. The only de-
scribed SNC8A nonsense mutat ion resul t ing in
haploinsufficiency was found in a patient with cerebel-
lar atrophy, ataxia, and mental retardation, but without
epilepsy [9]. Furthermore, functional studies of selected
missense mutation detected in an epileptic encephalop-
athy patient both confirm gain-of-function and loss-of-
function effects [3, 7, 8]. Given the fact that the
Nav1.6 channel is mainly located in excitatory neurons
[5], gain-of-function mutations would lead to increased
firing of the neuron, making the brain more sensitive
to epileptic discharges.
Dravet syndrome is caused by a loss-of-function
mutation in SCN1A, which encodes for the Nav1.1
channel, located in inhibitory neurons. In these pa-
tients, a truncating mutation or deletion in SCN1A
leads to a lack of well-functioning Nav1.1 channels.
Given the fact that Nav1.1 channels are located in in-
hibitory neurons, this leads to impaired inhibition and
therefore to increased excitation and epilepsy. There-
fore, mutations in SCN1A and SCN8A both present
clinically with epilepsy but probably have an opposite
working mechanism (loss-of-function mutation leading
to loss of inhibition, and gain-of-function mutation
leading to increased excitability of excitatory neurons,
respectively), both leading to increased excitability.
In patients with Dravet syndrome, sodium channel
blockers are contraindicated, possibly because blockage
of the remaining Nav1.1 will further impair inhibition
and increase neuron firing. On the contrary, for patients
with gain-of-function SCN8A mutations, we hypothe-
sized that sodium channel blockers could be beneficial.
Blocking the excessively firing Nav1.6 could decrease
the excitability of the neuron and have a counteracting
effect on the channel.
Results
Patient Descriptions and Response to Phenytoin
We report on 4 patients with a de novo missense mutation in
SCN8A and a remarkably good response on treatment with
phenytoin and loss of seizure control when phenytoin medi-
cation was reduced (see Table 1 for patient characteristics). All
patients had been antiepileptic drug resistant before the intro-
duction of phenytoin. Three patients have been seizure-free
since the initiation of phenytoin treatment, while seizure fre-
quency and severity has decreased significantly in one patient
(patient 1, Fig. 1). All mutations are reported using hg19 ref-
erence sequence and transcript ENST00000354534 and are
predicted as damaging.
Patient 1
Patient 1 is a 10-year-old girl who presented with tonic sei-
zures with apneas at the age of 4 months, followed by tonic–
clonic seizures. Early development before seizure onset was
normal; she currently has moderate psychomotor retardation
and ataxia, which could, in part, be due to phenytoin treat-
ment. She was initially treated with valproate and carbamaz-
epine. Later, topiramate was added and valproate was stopped.
At 7 months of age, she was diagnosed with a mitochondrial
encephalopathy, based on the findings of a muscle biopsy
showing decreased adenosine triphosphate production com-
bined with decreased complex II and III activity. Episodes of
severe seizures with saturation drops were treated with intra-
venous phenytoin. As it was noticed that this had an immedi-
ate, but also longer-lasting, favorable effect, she was treated
with increasing dosages of phenytoin over the following
years. Seizure severity and frequency decreased with increas-
ing phenytoin levels (Fig. 1). She showed a remarkable de-
pendency on increasingly high phenytoin levels, with seizures
occurring immediately when levels dropped below approxi-
mately 20 mg/l initially and 30 mg/l currently (therapeutic
range for total phenytoin levels 8–18 mg/l). The parents there-
fore determined phenytoin levels at least twice weekly, to
adjust dosage accordingly. She tolerated high phenytoin levels
well.With increasing seizure control, her developmental prog-
ress improved. A de novo heterozygous mutation in SCN8A
was detected in this patient, c.779T>C, p.Phe260Ser, which
was indicated to be damaging by in silico prediction. The
mitochondrial dysfunction is thought to be secondary to the
underlying monogenic epileptic encephalopathy. The clinical
phenotype has been described previously [4].
Patient 2
Patient 2 is a 2-year-old boy with seizure onset at the age of
5 months. Seizures were characterized by tonic spasms with
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cyanosis, and moments of staring with apnea at presentation.
Psychomotor development slowed after seizure onset and he
has, up to now, not developed speech. The boy was initially
treated with phenobarbital and valproate. Later, levetiracetam,
clobazam, and topiramate were subsequently added.
Clobazam was stopped because of behavioral problems.
While on this medication, he had a seizure frequency varying
from once per 5 weeks to 3 times daily. Frequent episodes of
otitis seemed to trigger the seizures. At the age of 14 months,
phenytoin was introduced because of increasing seizure fre-
quency. Upon the addition of phenytoin, the seizure frequency
decreased. Currently, he has been seizure-free for 6 months on
treatment with phenobarbital (currently being phased out),
valproate, and phenytoin, with total phenytoin levels between
14 and 24 mg/l, and psychomotor development is improving.
By targeted array analysis of epilepsy genes, a de novo het-
erozygous mutation in SCN8A, c.4787C>G (p.Ser1596Cys)
was detected. In silico prediction indicated this mutation as
possibly damaging.
Patient 3
Patient 3 is a 7-year-old boy who had his first seizure at the age
of 3.5 months. Seizures were tonic, with apnea, bradycardia,
and profound cyanosis, and came in clusters. They were often
provoked by infections or fever. In the first 2 years of life, he
had 3 episodes of status epilepticus. He was initially treated
with valproic acid, after which clobazam and carbamazepine
were added. Carbamazepine was later replaced by
oxcarbazepine, and valproic acid was stopped. Lamotrigine
was tried for 2 months but stopped because he developed a
rash. After another cluster of seizures at the age of 8 months,
phenytoin was started. With total phenytoin levels between 12
and 20 mg/l, he did not have any further seizures. Four repeat-
ed attempts to decrease the phenytoin dose resulted in im-
provement of cognitive and motor function, but exacerbation
of seizure activity, underlining the effectiveness of phenytoin
to control seizures in this patient. On occasion, phenytoin
levels were high (>30 mg/l) without the boy experiencing
complaints of intoxication, although he did have gingival hy-
perplasia since the start of treatment. At the age of 7 years,
brain magnetic resonance imaging showed marked cerebellar
atrophy, possibly as a side effect of phenytoin treatment.
Again, an attempt was made to decrease the phenytoin dosage
and to replace phenytoin with valproic acid. However, at total
phenytoin levels <10 mg/l he started to have seizures again
and phenytoin treatment was continued. Targeted array anal-
ysis of epilepsy genes showed a de novo heterozygous SCN8A
mutation, c.5610A>T p.Glu1870Asp, which was predicted to
be possibly damaging.
Patient 4
This patient is an 8-year-old girl with seizure onset at the age
of 6 weeks, after which she developed tonic, tonic–clonic,
myoclonic, and partial seizures. Multiple electroencephalo-
graphic recording showed multifocal epileptiform activity of
frontal, central, parietal, and temporal origin. At the age of
9 months treatment consisted of phenytoin, mysoline, and
clonazepam. She had an average of 10 tonic–clonic seizures
with apnea and cyanosis lasting for 2.0–2.5 min each day. Two
episodes of status epilepticus occurred at the age of 2 years,
when treated with levetiracetam, phenobarbital, zonisamide,
clonazepam, and phenytoin. She was treated with an extra
bolus of phenytoin intravenously (IV) and midazolam IV. At
the second episode low phenytoin serum concentration
(<1.6 mg/l) was detected and she was given additional phe-
nytoin IV. Thereafter, her daily phenytoin dosage was gradu-
ally increased from 7.5 mg to 36.0 mg 3 times daily, and a
serum concentration of 7.1 mg/l was achieved, after which no
major seizures occurred. Total phenytoin concentrations were
monitored and fluctuated between 2.8 and 8.4 mg/l. At the age
of 8 years, the cosmetic side effects of phenytoin
(hypertrichosis) were the reason for withdrawal of phenytoin
for an 8-week period, during which the patient immediately
developed almost daily tonic and tonic–clonic seizures during
sleep. At that time a genetic diagnosis was obtained using
whole-exome sequencing, which showed a de novo SCN8A
missense mutation c.2952C>G p.Asn984Lys [7]. Phenytoin
was reintroduced and the seizures stopped. Recently, the elec-
trophysiological properties of this mutation were studied else-
where, and the result predicted premature channel opening
and hyperactivity of neurons, compatible with the gain-of-
function effects reported previously [7].
Discussion
Here we describe 4 patients who carry a missense mutation in
SCN8A, in which seizure control is achieved by treatment with
Fig. 1 Phenytoin levels of patient 1. Red dots indicate hospital
admissions for increased seizure frequency
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(high-dose) phenytoin. Although this series of patients is rel-
atively small, the reoccurrence of seizures when serum phe-
nytoin levels were low in patient 1, and the reoccurrence of
seizures after multiple attempts to withdraw phenytoin in pa-
tients 3 and 4, provide a direct link between the genetic defect
in these patients and their drug response.
Phenytoin is a sodium channel blocker and binds at a re-
ceptor site in the pore of sodium channels, decreases the so-
dium influx, and thereby decreases the excitability of the neu-
ron. Given the fact that phenytoin is one of the few sodium
channel blockers targeting only the sodium channel and no
other molecular targets in the brain, this might explain the
extraordinary response to phenytoin treatment in our patients,
in contrast with the response to treatment with other sodium
channel blockers. Carbamazepine, another frequently used so-
dium channel blocker in epilepsy, is thought to have a similar
working mechanism to phenytoin. However, the affinity of
carbamazepine for inactivated sodium channels is around
three times lower than that of phenytoin [10]. Phenytoin
works in a frequency-dependent way: it is found primarily to
inhibit high-frequency firing but not low-frequency firing,
which explains the blocking effect of phenytoin on repetitive
discharges as seen in epilepsy, while not interfering with nor-
mal neuronal firing. Therefore, phenytoin could be an impor-
tant treatment option in patients with SCN8A-related epilepsy
because it is primarily expected to block the increased sodium
current through the mutated Nav1.6, but not to affect the func-
tion of other VGSC not affected by the SCN8Amutation. Side
effects of phenytoin include ataxia, nystagmus, cerebellar at-
rophy, and gingival hyperplasia. Cardiotoxicity (hypotension,
prolonged QT interval, arrhythmias) is rare after oral admin-
istration but is an important side effect after rapid phenytoin
administration IV. The therapeutic range of total phenytoin is a
serum level between 10 and 20 mg/l (free phenytoin 1–2 mg/
l). Total serum levels >20 mg/l may cause nystagmus, ataxia,
and tremor, while total serum levels >40 mg/l can lead to
lethargy, confusion, seizures, and coma [11].
The reported patients experienced side effects of phenyto-
in. However, both the physician and the patients’ parents con-
sidered the beneficial effects to outweigh the side effects. In
patient 1, only very high serum levels of >30 mg/l led to better
seizure control. Neurological side effects were acceptable,
which could possibly be explained by the alteration in
Nav1.6 function and neuronal excitability, making her proba-
bly less sensitive to phenytoin toxicity.
A previous functional study of the SCN8A mutation in
patient 4 demonstrated a gain-of-function effect in line with
the effect observed for the first SCN8A patient that was de-
scribed [7]. However, both gain- and loss-of-function effects
of SCN8A mutations have been described and further func-
tional studies of SCN8Amutations and corresponding phenyt-
oin response must be carefully examined to ensure adverse
reactions are avoided [3, 7, 8]. The described loss-of-
function effects of 2 different missense mutations may indi-
cate a dominant negative effect leading to a severe phenotype.
Alternatively, it remains possible that gain-of-function effects
have gone unobserved owing to the nature of the assay and
cell system used for functional characterization [3, 7]. Further
evaluation of putative loss-of-function mutations is needed, as
disease could be aggravated by phenytoin treatment in pa-
tients with loss-of-function SCN8A mutations. It therefore re-
mains uncertain if a beneficial effect of phenytoin depends on
the functional effects of missense mutations. Future studies
are also needed to overcome the low number of observations
and lack of control of confounders. However, based on the
findings in the abovementioned patients we consider treat-
ment with (high-dose) phenytoin as a possible treatment op-
tion in patients with difficult-to-control seizures due to an
SCN8A mutation. Dosing should be titrated gradually and
plasma levels above the supposed therapeutic window (i.e.,
Bsupratherapeutic^) might be required in order to obtain ac-
ceptable seizure control. Owing to saturation pharmacokinet-
ics of (phos)phenytoin, it is important to wait until steady state
is reached before increasing the dose further, especially when
aiming for supratherapeutic plasma levels. Finally, our obser-
vations should be interpreted with care given the low number
of patients and lack of control of confounders. Further obser-
vations and in vitro or in vivo modeling of the response of
SCN8A mutations to sodium blockers are needed.
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